A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596); A trial of the eastern cooperative oncology group

Leora Horn, Patricia Bernardo, Alan Sandler, Henry Wagner, Nathan Levitan, Mark L. Levitt, David H. Johnson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: To determine the 1-year survival, response rate, and toxicity for patients with limited stage small cell lung cancer treated with the combination of cisplatin plus etoposide plus paclitaxel with delayed concurrent (starting with cycle 3) high dose thoracic radiotherapy. Patients and Methods: Patients with previously untreated limited stage small cell lung cancer, Easter Cooperative Oncology Group performance status of 0-2 and adequate organ function were eligible. Cycles 1 and 2 of chemotherapy consisted of paclitaxel 170 mg/m2 intravenous day 1, etoposide 80 mg/m2 intravenous days 1 to 3, and cisplatin 60 mg/m2 intravenous day 1 followed by filgrastim 5 μg/kg subcutaneously days 4 to 13. Cycles 3 and 4 of chemotherapy consisted of a reduced dose of paclitaxel 135 mg/m2 intravenous day 1, and the same dose of etoposide and cisplatin with concurrent thoracic radiation therapy 1.8 Gy in 35 fractions (total 63 Gy) administered over 7 weeks. Results: Sixty-three patients were entered, 61 patients were eligible. The most common grade 4 toxicity seen was granulocytopenia (62%). Nonhematologic toxicities included febrile neutropenia in 19% of patients, grade 3 and 4 esophagitis in 32% of patients, and grade 3 peripheral neuropathy in 14% of patients. Two patients suffered lethal toxicities. The overall response rate was 79%. The 1-year survival rate was 64%. The median overall survival was 15.7 months, and the median progression-free survival was 8.6 months. Conclusions: The combination of cisplatin plus etoposide plus paclitaxel chemotherapy and concurrent delayed thoracic radiotherapy as administered in this trial provide no apparent advantage with respect to response, local control, or survival compared with historical controls.

Original languageEnglish (US)
Pages (from-to)527-533
Number of pages7
JournalJournal of Thoracic Oncology
Volume4
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Radiotherapy
Paclitaxel
Cisplatin
Thorax
Drug Therapy
Survival Rate
TP protocol
Febrile Neutropenia
Agranulocytosis
Survival
Esophagitis
Peripheral Nervous System Diseases
Disease-Free Survival

Keywords

  • Paclitaxel and etoposidecisplatin
  • Radiotherapy
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596); A trial of the eastern cooperative oncology group. / Horn, Leora; Bernardo, Patricia; Sandler, Alan; Wagner, Henry; Levitan, Nathan; Levitt, Mark L.; Johnson, David H.

In: Journal of Thoracic Oncology, Vol. 4, No. 4, 04.2009, p. 527-533.

Research output: Contribution to journalArticle

@article{7bb96efedd5b4e74a15d5b89958e78de,
title = "A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596); A trial of the eastern cooperative oncology group",
abstract = "Introduction: To determine the 1-year survival, response rate, and toxicity for patients with limited stage small cell lung cancer treated with the combination of cisplatin plus etoposide plus paclitaxel with delayed concurrent (starting with cycle 3) high dose thoracic radiotherapy. Patients and Methods: Patients with previously untreated limited stage small cell lung cancer, Easter Cooperative Oncology Group performance status of 0-2 and adequate organ function were eligible. Cycles 1 and 2 of chemotherapy consisted of paclitaxel 170 mg/m2 intravenous day 1, etoposide 80 mg/m2 intravenous days 1 to 3, and cisplatin 60 mg/m2 intravenous day 1 followed by filgrastim 5 μg/kg subcutaneously days 4 to 13. Cycles 3 and 4 of chemotherapy consisted of a reduced dose of paclitaxel 135 mg/m2 intravenous day 1, and the same dose of etoposide and cisplatin with concurrent thoracic radiation therapy 1.8 Gy in 35 fractions (total 63 Gy) administered over 7 weeks. Results: Sixty-three patients were entered, 61 patients were eligible. The most common grade 4 toxicity seen was granulocytopenia (62{\%}). Nonhematologic toxicities included febrile neutropenia in 19{\%} of patients, grade 3 and 4 esophagitis in 32{\%} of patients, and grade 3 peripheral neuropathy in 14{\%} of patients. Two patients suffered lethal toxicities. The overall response rate was 79{\%}. The 1-year survival rate was 64{\%}. The median overall survival was 15.7 months, and the median progression-free survival was 8.6 months. Conclusions: The combination of cisplatin plus etoposide plus paclitaxel chemotherapy and concurrent delayed thoracic radiotherapy as administered in this trial provide no apparent advantage with respect to response, local control, or survival compared with historical controls.",
keywords = "Paclitaxel and etoposidecisplatin, Radiotherapy, Small cell lung cancer",
author = "Leora Horn and Patricia Bernardo and Alan Sandler and Henry Wagner and Nathan Levitan and Levitt, {Mark L.} and Johnson, {David H.}",
year = "2009",
month = "4",
doi = "10.1097/JTO.0b013e31819c7daf",
language = "English (US)",
volume = "4",
pages = "527--533",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "4",

}

TY - JOUR

T1 - A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596); A trial of the eastern cooperative oncology group

AU - Horn, Leora

AU - Bernardo, Patricia

AU - Sandler, Alan

AU - Wagner, Henry

AU - Levitan, Nathan

AU - Levitt, Mark L.

AU - Johnson, David H.

PY - 2009/4

Y1 - 2009/4

N2 - Introduction: To determine the 1-year survival, response rate, and toxicity for patients with limited stage small cell lung cancer treated with the combination of cisplatin plus etoposide plus paclitaxel with delayed concurrent (starting with cycle 3) high dose thoracic radiotherapy. Patients and Methods: Patients with previously untreated limited stage small cell lung cancer, Easter Cooperative Oncology Group performance status of 0-2 and adequate organ function were eligible. Cycles 1 and 2 of chemotherapy consisted of paclitaxel 170 mg/m2 intravenous day 1, etoposide 80 mg/m2 intravenous days 1 to 3, and cisplatin 60 mg/m2 intravenous day 1 followed by filgrastim 5 μg/kg subcutaneously days 4 to 13. Cycles 3 and 4 of chemotherapy consisted of a reduced dose of paclitaxel 135 mg/m2 intravenous day 1, and the same dose of etoposide and cisplatin with concurrent thoracic radiation therapy 1.8 Gy in 35 fractions (total 63 Gy) administered over 7 weeks. Results: Sixty-three patients were entered, 61 patients were eligible. The most common grade 4 toxicity seen was granulocytopenia (62%). Nonhematologic toxicities included febrile neutropenia in 19% of patients, grade 3 and 4 esophagitis in 32% of patients, and grade 3 peripheral neuropathy in 14% of patients. Two patients suffered lethal toxicities. The overall response rate was 79%. The 1-year survival rate was 64%. The median overall survival was 15.7 months, and the median progression-free survival was 8.6 months. Conclusions: The combination of cisplatin plus etoposide plus paclitaxel chemotherapy and concurrent delayed thoracic radiotherapy as administered in this trial provide no apparent advantage with respect to response, local control, or survival compared with historical controls.

AB - Introduction: To determine the 1-year survival, response rate, and toxicity for patients with limited stage small cell lung cancer treated with the combination of cisplatin plus etoposide plus paclitaxel with delayed concurrent (starting with cycle 3) high dose thoracic radiotherapy. Patients and Methods: Patients with previously untreated limited stage small cell lung cancer, Easter Cooperative Oncology Group performance status of 0-2 and adequate organ function were eligible. Cycles 1 and 2 of chemotherapy consisted of paclitaxel 170 mg/m2 intravenous day 1, etoposide 80 mg/m2 intravenous days 1 to 3, and cisplatin 60 mg/m2 intravenous day 1 followed by filgrastim 5 μg/kg subcutaneously days 4 to 13. Cycles 3 and 4 of chemotherapy consisted of a reduced dose of paclitaxel 135 mg/m2 intravenous day 1, and the same dose of etoposide and cisplatin with concurrent thoracic radiation therapy 1.8 Gy in 35 fractions (total 63 Gy) administered over 7 weeks. Results: Sixty-three patients were entered, 61 patients were eligible. The most common grade 4 toxicity seen was granulocytopenia (62%). Nonhematologic toxicities included febrile neutropenia in 19% of patients, grade 3 and 4 esophagitis in 32% of patients, and grade 3 peripheral neuropathy in 14% of patients. Two patients suffered lethal toxicities. The overall response rate was 79%. The 1-year survival rate was 64%. The median overall survival was 15.7 months, and the median progression-free survival was 8.6 months. Conclusions: The combination of cisplatin plus etoposide plus paclitaxel chemotherapy and concurrent delayed thoracic radiotherapy as administered in this trial provide no apparent advantage with respect to response, local control, or survival compared with historical controls.

KW - Paclitaxel and etoposidecisplatin

KW - Radiotherapy

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=67649401025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649401025&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31819c7daf

DO - 10.1097/JTO.0b013e31819c7daf

M3 - Article

C2 - 19240650

AN - SCOPUS:67649401025

VL - 4

SP - 527

EP - 533

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 4

ER -